Article Per Year (5 Year)
p-Index From 2021 - 2026
0.444
P-Index
This Author published in this journals
All Journal Jurnal Farmasi Higea JKKI : Jurnal Kedokteran dan Kesehatan Indonesia
Maheswari, Ni Putu Devi
Unknown Affiliation
Medicine & Pharmacology Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
UJI FITOKIMIA DAN GUGUS FUNGSI EKSTRAK ETANOL DAUN Spondias pinnata (L.f.) Kurz Sari, Desak Made Vina Puspita; Permasutha, Made Bayu; Wiguna, Nyoman Intan Permatahati; Kurniawathi, Ni Luh Ranthi; Krisnadevi, I Gusti Agung Ayu Ari; Maheswari, Ni Putu Devi
Jurnal Farmasi Higea Vol 17, No 2 (2025)
Publisher : STIFARM Padang

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.52689/higea.v17i2.759

Abstract

Masyarakat Indonesia sampai saat ini masih sering menggunakan obat herbal karena manfaatnya dan harganya yang murah. Bali adalah daerah yang memanfaatkan tanaman sebagi obat-obatan, salah satunya adalah loloh daun cemcem. Loloh daun cemcem diyakini dapat menambah nafsu makan, mengurangi gejala batuk kering, memperlancar buang air kecil, mengontrol tekanan darah, meredakan panas dalam, mengembalikan cairan tubuh, dan obat pencahar. Penelitian ini bertujuan sebagai deteksi awal fitokimia dan validasi gugus fungsi yang dimiliki oleh ekstrak etanol daun cemcem. Proses ekstraksi pada penelitian ini menggunakan metode maserasi dengan pelarut etanol pronalisis. Uji fitokimia menganalisis alkaloid, flavonoid, fenolik, tanin, dan saponin. Analisis gugus fungsi dilakukan dengan metode Attenuated Total Reflectance-Fourier Transform Infrared (ATR-FTIR). Berdasarkan, pengujian fitokimia didapatkan bahwa senyawa metabolit sekunder alkaloid, flavonoid, fenolik, tanin, dan saponin terkandung dalam ekstrak etanol daun cemcem. Metode ATR-FTIR menunjukkan senyawa fenolik, flavonoid, tanin, dan glikosida karena teridentifikasinya gugus –OH, C–H, C=O, C=C, dan C–O.
Cilostazol or clopidogrel? Comparative evidence on bleeding risk, stroke recurrence, and mortality in ischemic stroke – A systematic review and meta-analysis Okaniawan, Kadek Kovaleviska; Maheswari, Ni Putu Devi; Okaniawan, Putu Enrico Pramana; Agustini, Ni Nyoman Mestri; Sastri, Ni Luh Putu Pranena
JKKI : Jurnal Kedokteran dan Kesehatan Indonesia JKKI, Vol 17, No 2, (2026)
Publisher : Faculty of Medicine, Universitas Islam Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20885/JKKI.Vol17.Iss2.art12

Abstract

Ischemic stroke remains a major contributor to global mortality and long-term disability, with antiplatelet therapy representing a fundamental strategy for secondary prevention. Cilostazol and clopidogrel are widely utilized antiplatelet agents; however, existing comparative evidence on their safety and efficacy, particularly regarding bleeding risk, stroke recurrence, and mortality, is inconsistent. This systematic review and meta-analysis aim to evaluate and compare the efficacy and safety of cilostazol versus clopidogrel in patients with ischemic stroke. The review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We conducted a comprehensive literature search across PubMed, Scopus, and Google Scholar up to September 2025. Eligible studies included randomized controlled trials and retrospective cohort studies directly comparing cilostazol and clopidogrel in adult patients with ischemic stroke. Multiple reviewers independently extracted data and selected studies using Covidence software to ensure consistency. We assessed risk of bias using the RoB 2.0 and ROBINS-I tools. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using Mantel–Haenszel methods. Eight studies comprising 8,249 participants were included in the analysis. Cilostazol was associated with lower risks of hemorrhagic complications (RR 0.77; 95% CI: 0.58–1.03) and mortality (RR 0.86; 95% CI: 0.70–1.04), although neither difference was statistically significant. No significant differences were identified between cilostazol and clopidogrel in recurrent ischemic stroke events or functional outcomes. Overall, both agents demonstrated comparable efficacy and safety profiles, supporting individualized treatment decisions based on clinical characteristics, bleeding risk, and comorbidities.
Co-Authors Krisnadevi, I Gusti Agung Ayu Ari Kurniawathi, Ni Luh Ranthi Made Bayu Permasutha Ni Luh Putu Pranena Sastri, Ni Luh Putu Pranena Ni Nyoman Mestri Agustini Okaniawan, Kadek Kovaleviska Okaniawan, Putu Enrico Pramana Sari, Desak Made Vina Puspita Wiguna, Nyoman Intan Permatahati